The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | TOURMALINE-MM3: undetectable MRD as an endpoint for maintenance therapy
Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, discusses results from the TOURMALINE-MM3 study (NCT02181413) of ixazomib vs placebo maintenance therapy in newly diagnosed multiple myeloma patients. Interestingly, TOURMALINE-MM3 used undetectable minimal residual disease as the clinical endpoint for this trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
